1Vallabh Janardhan,Philip AW,Carlos SK,et al.Anticardiolipin antibodies and risk of ischemic stroke and transient ischemic attack:the framingham cohort and offspring study[J].Stroke,2004,35(3):736-741.
8Famularo G,Antonell S,Barracchini A,et al.Catastrophic antiphospholipid syndrome in a patient with Behcet,sdisease[J].Scand J Rheumatol,2002,31(2):100.
5Manzi S, Meilatm EN, Rairie JE, et al. Age-specific incidence rates of myo-cardial infarction and angina in women with systemic lupus erythematosus: Comparison with the Framingham Study [J].Am J Epidemiol, 1997, 145 : 408- 415.
6Rahman P, Urowitz MB, Gladman DD, et al. Contribution of traditional risk factors to coronary artery disease in patients with systenfic erythematious[J]. J Rheum, 1999, 26:2 363-368.
7Haider YS, Roberts WC. Coronary arterial disease in systemic lupus erythematosus: quantification of degrees of narrowing in 22 necropsy patients (21 women)16 to 37 years [J]. Ant J Med, 1981, 70: 775-781.
8Soltesz P, Veres K, Lakos G, et al. Antiphospholipid antibodies in acute corn-nary syndrome[J].Ore Hetil, 2003, 144: 461-466.
9Gurlek A, Ozdol C, Pamir G, et al. Association between anticanrdioliopin anti-bodies and recurrent cardiac events in patients with acute coronary syndrome[J].Int Heart J, 2005, 46: 631-638.
10Ostanek L, Brzosko M, Fischer K, et al. Anfiphospholipid syndrome and an-fiphospholipid antibodies as a risk factors of ischaemic heart disease and myocardi-al infarction in patients with systemic lupos erythematosus[ J ]. Pol Arch Med Wewn, 2006, 115: 407-413.
